https://www.pharmaradar360.com/article/f8e0df31f36a72adPharmaRadar360en2026-04-29T10:54:31.000ZRECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2025 FINANCIAL STATEMENTS AND THE DIVIDEND OF €1.34 PER SHARE (+5.5% VS. 2024). NEW BOARD OF STATUTORY AUDITORS APPOINTEDhttps://www.pharmaradar360.com/article/e1c49476af887566PharmaRadar360en2026-04-29T10:22:59.000ZΑνακοίνωση σχετικά με την Ευρωπαϊκή Βάση Δεδομένων Ι/Π- EUDAMEDhttps://www.pharmaradar360.com/article/a0a3a5ce618a8d23PharmaRadar360en2026-04-29T08:46:13.000ZAπαγόρευση διάθεσης και διακίνησης των προϊόντωνhttps://www.pharmaradar360.com/article/2890daf5592b3bf8PharmaRadar360en2026-04-29T08:20:07.000ZEκτέλεση προϋπολογισμού μηνός Μαρτίου 2026https://www.pharmaradar360.com/article/2a431f0de2bbc8daPharmaRadar360en2026-04-29T06:34:07.000ZLa AEMPS adecúa los formatos de antibióticos para alinearlos con las pautas clínicas habituales y evitar su uso inapropiadohttps://www.pharmaradar360.com/article/50b26a601d0ccd1fPharmaRadar360en2026-04-29T06:01:54.000ZBoletín sobre Cosméticos, Biocidas AEMPS y Productos de Cuidado Personal. Enero-marzo 2026https://www.pharmaradar360.com/article/45bb611b8fa0992dPharmaRadar360en2026-04-29T03:47:50.000ZAcross the Codes: Navigating MedTech Compliance Expectations in the Regionhttps://www.pharmaradar360.com/article/1f39c8dc6825a66ePharmaRadar360en2026-04-29T02:00:00.000ZWegovy and Mounjaro for weight loss not fundedhttps://www.pharmaradar360.com/article/3322c5d249316645PharmaRadar360en2026-04-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/def9475ca5789751PharmaRadar360en2026-04-29T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/697bdc6471970d2fPharmaRadar360en2026-04-29T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/8cd8122f9566a2a5PharmaRadar360en2026-04-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/e4c9eb80d293e527PharmaRadar360en2026-04-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/6cdbf1b16c1b6686PharmaRadar360en2026-04-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/5a196b94719814a6PharmaRadar360en2026-04-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/03f2b4243b781af7PharmaRadar360en2026-04-29T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/3255b79cf0421b23PharmaRadar360en2026-04-29T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/a89700f353ea296aPharmaRadar360en2026-04-29T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/3aacbff0f0351387PharmaRadar360en2026-04-29T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/fc746fbafe0986b7PharmaRadar360en2026-04-29T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/ce3c3dbfc7428c9fPharmaRadar360en2026-04-29T00:00:00.000Z6203https://www.pharmaradar360.com/article/891b097db7b4d3b6PharmaRadar360en2026-04-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/71e03b0a0c896669PharmaRadar360en2026-04-29T00:00:00.000ZGSK delivers strong Q1 performance and start to 2026https://www.pharmaradar360.com/article/56765e6acc772634PharmaRadar360en2026-04-29T00:00:00.000ZUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directorshttps://www.pharmaradar360.com/article/4875a4b5bf7e7b09PharmaRadar360en2026-04-28T18:06:58.000ZWe fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatmenthttps://www.pharmaradar360.com/article/c6efa3cde128af63PharmaRadar360en2026-04-28T14:57:42.000ZFrom Blood Pressure Reduction to Cardiac Function: What New AVIM Therapy Data Signalhttps://www.pharmaradar360.com/article/86b04b1d15809cacPharmaRadar360en2026-04-28T12:00:00.000ZBepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDAhttps://www.pharmaradar360.com/article/c72e45ffe3a9b58cPharmaRadar360en2026-04-28T12:00:00.000ZAbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/31c65661d7569975PharmaRadar360en2026-04-28T11:00:00.000ZBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meetinghttps://www.pharmaradar360.com/article/0234acd6340e897bPharmaRadar360en2026-04-28T10:49:20.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/af2c1914c7250528PharmaRadar360en2026-04-28T10:45:00.000ZMerck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Strokehttps://www.pharmaradar360.com/article/0caf145164d598d5PharmaRadar360en2026-04-28T10:00:11.000ZClass 2 Medicines Recall: Amarox Limited, Sertraline 100mg film-coated tablets, EL(26)A/22https://www.pharmaradar360.com/article/fef0238bf3a8443fPharmaRadar360en2026-04-28T09:40:57.000ZΓενόσημα Μαρτίου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/23227cfb6eda5d1fPharmaRadar360en2026-04-28T09:30:22.000ZCuidar de las personas, construir prevenciónhttps://www.pharmaradar360.com/article/39d65b206f64d674PharmaRadar360en2026-04-28T09:07:38.000ZΑνάκληση των παρτίδων του συνημμένου πίνακα του Ιατροτεχνολογικου προϊόντος, MDD Class IIΙ, 16F Dual—Valved Splittable Sheath Introducerhttps://www.pharmaradar360.com/article/b73bf4319d4c3f39PharmaRadar360en2026-04-28T08:55:15.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/03acf7e7b84c8e3bPharmaRadar360en2026-04-28T08:30:01.000ZCorporate report: MHRA Results and Forecast 2025/26; 2026/27https://www.pharmaradar360.com/article/b900ea4dd2d27af0PharmaRadar360en2026-04-28T08:27:20.000ZField Safety Notices: 20 to 24 April 2026https://www.pharmaradar360.com/article/09ee7de185d8aa17PharmaRadar360en2026-04-28T08:23:31.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/b04bf8ed33f54042PharmaRadar360en2026-04-28T08:00:00.000ZMedtronic announces CE Mark for Stealth AXiS™ surgical systemhttps://www.pharmaradar360.com/article/9012c0476fb7d655PharmaRadar360en2026-04-28T00:00:00.000ZU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutationshttps://www.pharmaradar360.com/article/fb06626cb5848656PharmaRadar360en2026-04-28T00:00:00.000ZTaiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Developmenthttps://www.pharmaradar360.com/article/f4534ddf982343f6PharmaRadar360en2026-04-28T00:00:00.000ZShop — Petro's Chili & Chips™https://www.pharmaradar360.com/article/5f0df45cb4feb924PharmaRadar360en2026-04-28T00:00:00.000ZMenu — Petro's Chili & Chips™https://www.pharmaradar360.com/article/642dc01a7be358c1PharmaRadar360en2026-04-28T00:00:00.000ZPetro's Chili & Chips™https://www.pharmaradar360.com/article/4df9e50bf249cffcPharmaRadar360en2026-04-28T00:00:00.000Z404 Error — Petro's Chili & Chips™https://www.pharmaradar360.com/article/f4ef38222f6eb5ecPharmaRadar360en2026-04-28T00:00:00.000ZTips for Properly Washing Your Producehttps://www.pharmaradar360.com/article/d3ca9ee9df54b104PharmaRadar360en2026-04-28T00:00:00.000ZCleveland Clinic Recognized as a National Historic Chemical Landmark for Serotonin Discoveryhttps://www.pharmaradar360.com/article/29bd596b73b193f2PharmaRadar360en2026-04-27T23:01:01.000ZInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelineshttps://www.pharmaradar360.com/article/a6862dc7309468e2PharmaRadar360en2026-04-27T23:01:01.000ZClinical trials for medicines: non-investigational medicinal productshttps://www.pharmaradar360.com/article/b3597069306f2b3bPharmaRadar360en2026-04-27T23:01:01.000ZClinical trials for medicines: good manufacturing practice and radiopharmaceutical investigational medicinal productshttps://www.pharmaradar360.com/article/a76f75508aeb9605PharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical Trials Regulations enforcement provisionshttps://www.pharmaradar360.com/article/da56f4ec834b93afPharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/cb11560279c42d6bPharmaRadar360en2026-04-27T23:01:01.000ZGuidance: Clinical trials for medicines: Archiving and retention of clinical trial recordshttps://www.pharmaradar360.com/article/664451feb5b37f3ePharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: notifiable trialshttps://www.pharmaradar360.com/article/cf9746c41f4528a5PharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: labellinghttps://www.pharmaradar360.com/article/a12171476184f39cPharmaRadar360en2026-04-27T23:01:00.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/45aaaec4dd9b9189PharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: International Council for Harmonisation (ICH) annotationshttps://www.pharmaradar360.com/article/013df3e7c83daad6PharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: Notification of Serious Breaches of GCP or the trial protocolhttps://www.pharmaradar360.com/article/cdd8299e99c8a32dPharmaRadar360en2026-04-27T23:01:00.000ZGuidance: Clinical trials for medicines: Declaration of Helsinki and Clinical Trial Regulations alignmenthttps://www.pharmaradar360.com/article/301195f612f311faPharmaRadar360en2026-04-27T20:13:16.000ZLeading the Cut: 4 Organizations Take on Site Training Reductionhttps://www.pharmaradar360.com/article/e9cc65bf1db4a7dcPharmaRadar360en2026-04-27T19:59:58.000ZMAb-based immunosuppressant supports crucial diabetes cell transplantshttps://www.pharmaradar360.com/article/cf2f9337322793fdPharmaRadar360en2026-04-27T16:00:00.000ZUS legislative reforms needed to make biosimilars competitive